-
Orchard Therapeutics Highlights 2020 Strategic Priorities
Orchard Therapeutics Highlights 2020 Strategic Priorities -
Disarm Therapeutics Appoints Veteran Biotech Executive Scott Holmes as Chief Financial Officer
Disarm Therapeutics Appoints Veteran Biotech Executive Scott Holmes as Chief Financial Officer -
Dyne Therapeutics Announces Appointment of Molly White as Vice President, Medical Communications and Advocacy
Dyne Therapeutics Announces Appointment of Molly White as Vice President, Medical Communications and Advocacy -
LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones
LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones -
Generation Bio Announces $110 Million Series C Financing to Advance Lead Programs for Hemophilia A and PKU
Generation Bio Announces $110 Million Series C Financing to Advance Lead Programs for Hemophilia A and PKU -
Top Life Sciences Startups to Watch in 2020
Top Life Sciences Startups to Watch in 2020 -
Triplet Therapeutics Launches with $59 Million in Financing to Further its Development of Transformative Treatments for Triplet Repeat Disorders
Triplet Therapeutics Launches with $59 Million in Financing to Further its Development of Transformative Treatments for Triplet Repeat Disorders -
Orchard Therapeutics Announces the Filing and Validation of Marketing Authorization Application by European Medicines Agency for OTL-200 for the Treatment of Metachromatic Leukodystrophy
Orchard Therapeutics Announces the Filing and Validation of Marketing Authorization Application by European Medicines Agency for OTL-200 for the Treatment of Metachromatic Leukodystrophy -
Aurinia stock soars after breakthrough drug for lupus victims has positive trials
Aurinia stock soars after breakthrough drug for lupus victims has positive trials -
Sigilon Therapeutics to Present Preclinical Data Showing Six Months Durability for Cell Therapies in Rare Blood Disorders
Sigilon Therapeutics to Present Preclinical Data Showing Six Months Durability for Cell Therapies in Rare Blood Disorders -
Orchard Therapeutics Highlights 2020 Strategic Priorities
Orchard Therapeutics Highlights 2020 Strategic Priorities
-
Disarm Therapeutics Appoints Veteran Biotech Executive Scott Holmes as Chief Financial Officer
Disarm Therapeutics Appoints Veteran Biotech Executive Scott Holmes as Chief Financial Officer
-
Dyne Therapeutics Announces Appointment of Molly White as Vice President, Medical Communications and Advocacy
Dyne Therapeutics Announces Appointment of Molly White as Vice President, Medical Communications and Advocacy
-
LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones
LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones
-
Generation Bio Announces $110 Million Series C Financing to Advance Lead Programs for Hemophilia A and PKU
Generation Bio Announces $110 Million Series C Financing to Advance Lead Programs for Hemophilia A and PKU
-
Top Life Sciences Startups to Watch in 2020
Top Life Sciences Startups to Watch in 2020
-
Triplet Therapeutics Launches with $59 Million in Financing to Further its Development of Transformative Treatments for Triplet Repeat Disorders
Triplet Therapeutics Launches with $59 Million in Financing to Further its Development of Transformative Treatments for Triplet Repeat Disorders
-
Orchard Therapeutics Announces the Filing and Validation of Marketing Authorization Application by European Medicines Agency for OTL-200 for the Treatment of Metachromatic Leukodystrophy
Orchard Therapeutics Announces the Filing and Validation of Marketing Authorization Application by European Medicines Agency for OTL-200 for the Treatment of Metachromatic Leukodystrophy
-
Aurinia stock soars after breakthrough drug for lupus victims has positive trials
Aurinia stock soars after breakthrough drug for lupus victims has positive trials
-
Sigilon Therapeutics to Present Preclinical Data Showing Six Months Durability for Cell Therapies in Rare Blood Disorders
Sigilon Therapeutics to Present Preclinical Data Showing Six Months Durability for Cell Therapies in Rare Blood Disorders
-
Orchard Therapeutics Highlights 2020 Strategic Priorities
Orchard Therapeutics Highlights 2020 Strategic Priorities
-
Disarm Therapeutics Appoints Veteran Biotech Executive Scott Holmes as Chief Financial Officer
Disarm Therapeutics Appoints Veteran Biotech Executive Scott Holmes as Chief Financial Officer
-
Dyne Therapeutics Announces Appointment of Molly White as Vice President, Medical Communications and Advocacy
Dyne Therapeutics Announces Appointment of Molly White as Vice President, Medical Communications and Advocacy
-
LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones
LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones
-
Generation Bio Announces $110 Million Series C Financing to Advance Lead Programs for Hemophilia A and PKU
Generation Bio Announces $110 Million Series C Financing to Advance Lead Programs for Hemophilia A and PKU
-
Top Life Sciences Startups to Watch in 2020
Top Life Sciences Startups to Watch in 2020
-
Triplet Therapeutics Launches with $59 Million in Financing to Further its Development of Transformative Treatments for Triplet Repeat Disorders
Triplet Therapeutics Launches with $59 Million in Financing to Further its Development of Transformative Treatments for Triplet Repeat Disorders
-
Orchard Therapeutics Announces the Filing and Validation of Marketing Authorization Application by European Medicines Agency for OTL-200 for the Treatment of Metachromatic Leukodystrophy
Orchard Therapeutics Announces the Filing and Validation of Marketing Authorization Application by European Medicines Agency for OTL-200 for the Treatment of Metachromatic Leukodystrophy
-
Aurinia stock soars after breakthrough drug for lupus victims has positive trials
Aurinia stock soars after breakthrough drug for lupus victims has positive trials
-
Sigilon Therapeutics to Present Preclinical Data Showing Six Months Durability for Cell Therapies in Rare Blood Disorders
Sigilon Therapeutics to Present Preclinical Data Showing Six Months Durability for Cell Therapies in Rare Blood Disorders